Commitments and Contingencies - License Agreements (Details) - TMRC - USD ($) $ in Millions |
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2016 |
May 31, 2016 |
Sep. 30, 2015 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||||
| Up-front license fee | $ 1.0 | ||||
| Payment of up-front license fee | $ 0.5 | 0.5 | |||
| Payments per indication due upon the successful achievement of clinical and regulatory milestones | $ 13.0 | ||||
| Payments made upon achievement of development milestone | $ 1.0 | ||||
| Payments made under the supply management agreement | $ 0.0 | $ 0.4 | |||
| X | ||||||||||
- Definition Payments made per the license agreement, for a development milestone achieved. No definition available.
|
| X | ||||||||||
- Definition The payments per indication due upon the successful achievement of clinical and regulatory milestones. No definition available.
|
| X | ||||||||||
- Definition Represents payments made under the supply management agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of the up-front license fee. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of the up-front license fee payments made during the period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|